Regular PaperMatrix metalloproteinases and tumor invasion: from correlation and causality to the clinic
References (0)
Cited by (343)
Nutraceuticals in cancer prevention
2021, Nutraceuticals: Efficacy, Safety and ToxicityPeptide decorated gold nanoparticle/carbon nanotube electrochemical sensor for ultrasensitive detection of matrix metalloproteinase-7
2020, Sensors and Actuators, B: ChemicalMitigation of arsenic-induced acquired cancer phenotype in prostate cancer stem cells by miR-143 restoration
2016, Toxicology and Applied PharmacologyCitation Excerpt :However, upon miR-143 overexpression in these As-CSC cells, there was a marked inhibition of MMP-9 and MMP-2 activities. Considering the important roles of MMPs in carcinogenesis as modulators of the tumor microenvironment (Bachmeier et al., 2000; Kessenbrock et al., 2010; Radisky and Radisky, 2010; Stetler-Stevenson et al., 1996), the observed decrease in MMP-9 and MMP-2 activities in response to miR-143 overexpression is indicative of a diminished cancer phenotype in the As-CSCs. The ability of cancer cells to expand in number is dependent on both the rate of cell proliferation and cell death, mainly by apoptosis.
Expression, purification, refolding and in vitro recovery of active full length recombinant human gelatinase MMP-9 in Escherichia coli
2016, Protein Expression and PurificationProteases in cancer drug delivery
2016, Advanced Drug Delivery ReviewsHow to tackle protein structural data from solution and solid state: An integrated approach
2016, Progress in Nuclear Magnetic Resonance SpectroscopyCitation Excerpt :Most MMPs comprise a prodomain that is removed upon activation, a catalytic domain responsible for hydrolytic activity, and a hemopexin-like domain that probably plays a role in substrate recognition. In several pathologies, overexpression of MMPs, or misregulation of their activity, is related to disease progression [173–175]. MMPs are thus validated pharmaceutical targets.